Emerging incretin- and multi-agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond

2026/01/20 by Emir Muzurović, Niki Katsiki, Špela Volčanšek +3
Medicine · Neuroscience · #Diabetes Treatment and Management #Bariatric Surgery and Outcomes #Regulation of Appetite and Obesity

paper · doi:10.1016/j.metabol.2026.156494

Citations

• Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
• New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications
• Adherence to the EAT-Lancet diet, genetic susceptibility, and risk of type 2 diabetes in Swedish adults
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
• Pathophysiology of sarcopenia: Genetic factors and their interplay with environmental factors